Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Leveljump HealthcareTSXV:JUMP Piotroski F-Score is 4 as of Jul. 21, 2026, which is at its 10-year median of 4.00. The stock has 1 warning sign investors should review. Among 208 Medical Diagnostics & Research companies, Leveljump Healthcare ranks better than 94.71% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Leveljump Healthcare has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Leveljump Healthcare's Piotroski F-Score or its related term are showing as below:
TSXV:JUMP'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 7
Current: 4
During the past 7 years, the highest Piotroski F-Score of Leveljump Healthcare was 7. The lowest was 2. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Leveljump Healthcare Piotroski F-Score Related Terms
Leveljump Healthcare Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Leveljump Healthcare's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:JUMP vs TMO, DHR, IDXX: Piotroski F-Score Comparison
For the Diagnostics & Research subindustry, Leveljump Healthcare's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leveljump Healthcare Piotroski F-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Leveljump Healthcare's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Leveljump Healthcare's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Leveljump Healthcare's current Net Income (TTM) was -3.63.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Leveljump Healthcare's return on assets of this year was -0.16659779. Leveljump Healthcare's return on assets of last year was 0.10571978.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Leveljump Healthcare's gearing of this year was 0.31477595. Leveljump Healthcare's gearing of last year was 0.34197747.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Leveljump Healthcare's current ratio of this year was 0.20507545. Leveljump Healthcare's current ratio of last year was 0.46919285.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Leveljump Healthcare's number of shares in issue this year was 99.135. Leveljump Healthcare's number of shares in issue last year was 109.935.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Leveljump Healthcare's gross margin of this year was 0.18325287. Leveljump Healthcare's gross margin of last year was 0.19959456.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Leveljump Healthcare's asset turnover of this year was 0.8845571. Leveljump Healthcare's asset turnover of last year was 0.9482051.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
0
+
1
+
1
+
0
+
1
+
0
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Leveljump Healthcare has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Leveljump Healthcare (TSXV:JUMP) has a Piotroski F-Score of 4 as of Jul. 21, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Leveljump Healthcare and its competitors. This is near median its historical median of 4.00. Over the past decade, Leveljump Healthcare's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Leveljump Healthcare ranks #11 out of 208 companies in the Medical Diagnostics & Research industry, placing it in the top 5.3%.
Is Leveljump Healthcare's Piotroski F-Score too high?
Leveljump Healthcare's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Leveljump Healthcare's value of 4 is 20% below this industry median. Based on the distribution chart, Leveljump Healthcare ranks #11 out of 208 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Leveljump Healthcare's Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Leveljump Healthcare ranks #11 out of 208 companies for Piotroski F-Score. This places Leveljump Healthcare in the top 5% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Leveljump Healthcare's value of 4 is 20% below this benchmark. Historically, Leveljump Healthcare's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Leveljump Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 208 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Leveljump Healthcare's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Leveljump Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Leveljump Healthcare's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leveljump Healthcare stock overvalued right now?
Leveljump Healthcare (TSXV:JUMP) has a current Piotroski F-Score of 4. The stock's GF Value™ is C$0.07, compared to a current price of C$0.06 — trading 21.4% below its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Diagnostics & Research industry median of 5.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Leveljump Healthcare (TSXV:JUMP), the current Piotroski F-Score is 4 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Leveljump Healthcare Corp is engaged in providing radiology services both by providing direct patient images and by providing Teleradiology services, which is the process of providing remote off-site reading of radiology scans such as CT, MRI, and X-ray. Its teleradiology services allow hospital staff to scan their emergency room patients, then page the company's radiologist on call, who can then remotely view, via a secured server, the images and diagnose the patient, and provide a report back to the hospital. Leveljump provides its direct-to-patient services at its Independent Healthcare Facilities (IHFs). The company operates as a single segment, with all of its core assets, intellectual property, and development work being conducted in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:JUMP has been successfully added to your 
